Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer

BackgroundProgrammed death receptor-1 (PD-1) blockade shows little benefit in patients with microsatellite-stable colorectal cancer (MSS-CRC). Fruquintinib is a China-made anti-angiogenic drug which is approved for the third line therapy in mCRC. This study investigates the effect of the combination...

Full description

Bibliographic Details
Main Authors: Qingli Li, Xiaojiao Cheng, Cong Zhou, Yao Tang, Fuli Li, Baiwen Zhang, Tinglei Huang, Jianzheng Wang, Shuiping Tu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
fruquintinib
sintilimab
immunotherapy
microsatellite stable colorectal cancer
anti-angiogenesis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.841977/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.841977/full

Similar Items